China's Duality Biotherapeutics shares rise more than double in Hong Kong debut
- QUANTUNG PHARMA
- Apr 14
- 1 min read
Summary
Companies
Duality increased share offering due to high demand, regulatory filings show
Retail investors oversubscribed shares by 115 times, institutional by 13.5 times
Eleven cornerstone investors subscribed to $65 million worth of stock
, opens new tab stock more than doubled on its Hong Kong debut on Tuesday, achieving the best first-day trading performance following an IPO in the city in four years.
The Chinese biotech firm raised $213 million in an initial public offering launched the day financial markets reacted savagely to a U.S. tariffs announcement.
